Statement from FDA Commissioner Scott Gottlieb, M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA’s new drug review programs https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596897.htm